TAK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic Hypersomnia | TAKLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2 | TAKLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04009109Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · Myeloma, MultipleActive, not recruitingBMYCollaboratorTAKCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal DementiaActive, not recruitingDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06249555VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational StudyAlimentiv Inc. · Crohn's DiseaseActive, not recruitingTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimateNo phase registeredNCT05844033Biomarker for Infection Risk in CLL and MMMassachusetts General Hospital · Multiple MyelomaActive, not recruitingTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 3NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda · Narcolepsy Type 1 (NT1)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT05013190A Study of NINLARO® in Chinese Adults With Multiple MyelomaTakeda · Multiple MyelomaActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT05469789A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Takeda · Hereditary Angioedema (HAE)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07299097Epidemiology of Narcolepsy Type 1 and Type 2 in SpainTakeda · Narcolepsy Type 1Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 2NCT07011576A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)SCRI Development Innovations, LLC · Colon CancerRecruitingTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2027Sponsor estimateNo phase registeredNCT05100056A Study of Brentuximab Vedotin in Adults With Hodgkin's LymphomaTakeda · Hodgkin LymphomaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2027Sponsor estimatePhase 3NCT05319353A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of...Takeda · Cytomegalovirus (CMV)RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2027Sponsor estimateNo phase registeredNCT07787767CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in ArgentinaHospital Italiano de Buenos Aires · Cytomegalovirus InfectionsNot yet recruitingTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimateNo phase registeredNCT06243731A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After TransplantationTakeda · Cytomegalovirus (CMV)RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
- Primary completion Feb 1, 2027Sponsor estimateNo phase registeredNCT04869280Post-Marketing Study of Prucalopride Safety In PregnancyTakeda · Chronic Idiopathic Constipation (CIC)Active, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2027Sponsor estimatePhase 2NCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaTakeda · Hidradenitis SuppurativaActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06973304A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeTakeda · Short Bowel SyndromeActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2027Sponsor estimateNo phase registeredNCT05879757Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary ImmunodeficiencyTakeda · Multiple MyelomaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2027Sponsor estimatePhase 2NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active...Takeda · Crohn's DiseaseRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 20 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.